Financial Review: Xilio Therapeutics (XLO) versus The Competition

Xilio Therapeutics (NASDAQ:XLOGet Rating) is one of 952 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Xilio Therapeutics to similar businesses based on the strength of its analyst recommendations, earnings, valuation, institutional ownership, profitability, risk and dividends.

Profitability

This table compares Xilio Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Xilio Therapeutics N/A -91.19% -45.94%
Xilio Therapeutics Competitors -3,209.16% -160.26% -24.32%

Analyst Recommendations

This is a summary of current ratings for Xilio Therapeutics and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xilio Therapeutics 0 0 5 0 3.00
Xilio Therapeutics Competitors 3103 13051 39246 634 2.67

Xilio Therapeutics presently has a consensus price target of $25.50, indicating a potential upside of 719.94%. As a group, “Pharmaceutical preparations” companies have a potential upside of 97.66%. Given Xilio Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Xilio Therapeutics is more favorable than its rivals.

Insider and Institutional Ownership

64.7% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 42.5% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 3.5% of Xilio Therapeutics shares are owned by company insiders. Comparatively, 15.0% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Xilio Therapeutics and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Xilio Therapeutics N/A -$75.80 million -0.13
Xilio Therapeutics Competitors $1.84 billion $245.93 million -3.87

Xilio Therapeutics’ rivals have higher revenue and earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Xilio Therapeutics beats its rivals on 7 of the 12 factors compared.

About Xilio Therapeutics

(Get Rating)

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.